Warfarin genotyping with hybridization-induced aggregation on a poly(ethylene terephthalate) microdevice.

Analyst

Department of Chemistry, University of Virginia, Charlottesville, Virginia 22904, USA. and Department of Pathology, University of Virginia, Charlottesville, Virginia 22908, USA and Department of Mechanical Engineering, University of Virginia, Charlottesville, Virginia 22904, USA.

Published: January 2017

AI Article Synopsis

  • Warfarin is a widely used blood thinner that has a narrow therapeutic index and significant variability in how individuals respond, leading to it being a common cause of drug-related ER visits.
  • Genetic factors greatly influence warfarin sensitivity, and using a genotype-guided dosing strategy could help prevent adverse events.
  • A new method for genotyping warfarin sensitivity, using multiplex PCR with a quick detection technique, was found to provide accurate results rapidly and affordably, making it suitable for routine clinical use.

Article Abstract

Warfarin, a commonly prescribed oral anticoagulant, is burdened by a narrow therapeutic index and high inter-individual variability in response, making it the second leading cause of drug-related emergency room visits. Since genetic factors contribute significantly to warfarin sensitivity, a genotype-guided dosing strategy may reduce the occurrence of adverse events. While numerous methods have been demonstrated for warfarin genotyping, the specifications of most assays with respect to turnaround time and cost are not ideal for routine testing. Here, we present a unique method for warfarin genotyping based on multiplex PCR coupled with Hybridization-induced Aggregation (HIA), a bead-based technique for sequence-specific detection. A multiplex allele-specific PCR reaction was used to generate products corresponding to 3 genetic variants associated with warfarin sensitivity [CYP2C9 *2, CYP2C9 *3, and VKORC1 (1173C>T)] and an internal control product. The products were detected simultaneously on a poly(ethylene terephthalate) (PeT) microdevice using HIA, which provided genotyping results in approximately 15 minutes following PCR. The genotyping results of 23 patient DNA samples using this approach were in 100% concordance with the results of a validated test (WARFGENO test, ARUP laboratories). Additionally, the PCR reaction was successfully transferred to a PeT chip, which provided accurate genotyping results from patient DNA samples in under an hour. This work demonstrates a simple, rapid, and affordable approach to warfarin genotyping based on multiplex allele-specific PCR coupled with HIA detection. By demonstrating both chemistries on PeT microdevices, we show the potential for integration on a single device for sample-to-answer genotyping.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c6an02325hDOI Listing

Publication Analysis

Top Keywords

warfarin genotyping
16
hybridization-induced aggregation
8
polyethylene terephthalate
8
warfarin sensitivity
8
genotyping based
8
based multiplex
8
pcr coupled
8
multiplex allele-specific
8
allele-specific pcr
8
pcr reaction
8

Similar Publications

Warfarin is the most widely used oral anticoagulant in clinical practice. The cytochrome P450 2C9 (CYP2C9), vitamin K epoxide reductase complex 1 (VKORC1), and cytochrome P450 4F2 (CYP4F2) genotypes are associated with warfarin dose requirements in China. Accurate genotyping is vital for obtaining reliable genotype-guided warfarin dosing information.

View Article and Find Full Text PDF

Implementation of pharmacogenetic testing in clinical care has been slow and with few exceptions is hindered by the lack of real-world evidence on how to best target testing. In this retrospective register-based study, we analyzed a nationwide cohort of 1,425,000 patients discharged from internal medicine or surgical wards and a cohort of 2,178 university hospital patients for purchases and prescriptions of pharmacogenetically actionable drugs. Pharmacogenetic variants were obtained from whole genome genotype data for a subset (n = 930) of the university hospital patients.

View Article and Find Full Text PDF

Objective: Warfarin has a narrow therapeutic window and large variability in dosing that are affected by clinical and genetic factors. To help guide the dosing of warfarin, the Clinical Pharmacogenetics Implementation Consortium has recommended the use of pharmacogenetic algorithms, such as the ones developed by the International Warfarin Pharmacogenetics Consortium (IWPC) and by Gage et al. when genotype information is available.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to explore how specific genetic variations (CYP2C9*2, *3, VKORC1-1639 G>A, and CYP4F2*3) affect warfarin dosing in an Arab population and to compare the effectiveness of genetic versus clinical dosing algorithms during warfarin initiation.
  • Involving 130 Arab patients, the research involved calculating initial warfarin doses using a clinical algorithm and subsequently using genetic data to determine more accurate dosing after a month.
  • Results indicated that genetic variations significantly influenced the required warfarin dose, with genetic dosing algorithms providing more accurate dose estimates than clinical methods based on a lower median absolute error.
View Article and Find Full Text PDF

Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.

Blood Adv

October 2024

Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.

Article Synopsis
  • Warfarin dosing is affected by individual clinical and genetic factors, with a need to explore genetic variants specific to African populations for better dosing guidance.
  • A genome-wide association study (GWAS) focused on 989 warfarin-treated participants from Uganda, South Africa, and Zimbabwe, as well as African American cohorts, found significant genetic variants associated with warfarin response.
  • The study highlighted the importance of the CYP2C9 and VKORC1 genes and identified a new potential genetic locus (MALL) that may impact warfarin response, warranting further research to understand its biological relevance.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!